Surrogate Endpoints Are Dangerous Path For New Antibiotics – JAMA Editorial
Expedited pathways for acute bacterial infection treatments may increase number of new products at expense of safety and effectiveness, University of Washington doctors warn in JAMA Internal Medicine. Authors criticized trial designs used for Cubist’s Sivextro, Durata’s Dalvance and Theravance’s Vibativ.
You may also be interested in...
Both antibiotics gain a strong positive recommendation from FDA advisory committee, but questions about how skin lesions were measured before and during treatment persist as experience with new endpoint increases.
The Anti-Infective Drugs Advisory Committee votes 13-2 in favor of a limited indication for Theravance’s antibiotic, particularly for use in treating methicillin-resistant infections. The endorsement comes after a nearly four-year regulatory battle over the NDA.
Even as the US FDA can expect to be put through the ringer with the congressional and HHS Inspector General probes, the process could have some upsides for the agency, according to former officials who have been through such scrutiny.